Oprelvekin

Results: 21



#Item
1The ITP Support Association ___________________________________________

The ITP Support Association ___________________________________________

Add to Reading List

Source URL: www.itpsupport.org.uk

Language: English - Date: 2007-03-29 07:19:45
2IL-11 Interleukin-11, adipogenesis inhibitory factor human, recombinant, E. coli Cat. No.

IL-11 Interleukin-11, adipogenesis inhibitory factor human, recombinant, E. coli Cat. No.

Add to Reading List

Source URL: www.jenabioscience.com

Language: English - Date: 2014-04-14 06:04:56
3Clinical Pharmacokinetics BLA: 961433, recombinant human Interleukin  Review

Clinical Pharmacokinetics BLA: 961433, recombinant human Interleukin Review

Add to Reading List

Source URL: www.fda.gov

Language: English
4Oprelvekin, (Neumega) Genetics Institute, Inc.

Oprelvekin, (Neumega) Genetics Institute, Inc.

Add to Reading List

Source URL: www.fda.gov

Language: English
5F1452 F[removed]CEDAX®   (ceftibuten capsules) and (ceftibuten for oral suspension)

F1452 F[removed]CEDAX® (ceftibuten capsules) and (ceftibuten for oral suspension)

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:51:29
6Oprelvekin, (Neumega) Genetics Institute, Inc.

Oprelvekin, (Neumega) Genetics Institute, Inc.

Add to Reading List

Source URL: www.fda.gov

Language: English
7WYETH-AYERST  ® 150 NORTH RADNOR-CHESTER ROAD • ST. DAVIDS, PA 19087

WYETH-AYERST ® 150 NORTH RADNOR-CHESTER ROAD • ST. DAVIDS, PA 19087

Add to Reading List

Source URL: www.fda.gov

Language: English
8Transfusion medicine / Hematology / Plateletpheresis / Thrombocytopenia / Oprelvekin / Platelet / Blood transfusion / Chemotherapy / Apheresis / Medicine / Biology / Blood

1 DEPARTMENT OF HEALTH AND HUMAN SERVICES

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 1998-03-12 09:39:13
9-----------------------WARNINGS AND PRECAUTIONS-----------------------­ • Hepatotoxicity: Fatal hepatotoxicity occurred in 0.2% of patients. Monitor with periodic liver testing. Temporarily suspend, dose reduce, or pe

-----------------------WARNINGS AND PRECAUTIONS-----------------------­ • Hepatotoxicity: Fatal hepatotoxicity occurred in 0.2% of patients. Monitor with periodic liver testing. Temporarily suspend, dose reduce, or pe

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-11-22 15:40:20
10_______________  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing information for JAKAFI.

_______________ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing information for JAKAFI.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-11-26 15:13:16